NCT07259018尚未招募不适用
A Single-arm, Open Label, Single-center Early Feasibility Study of the LuSeed Aneurysm Embolization System in Individuals With Unruptured Intracranial Aneurysms.
LuSeed Vascular LTD.2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年12月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Primary Safety Endpoint
研究概览
简要总结
The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a single-arm, open-label, single-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 10 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled in a Canadian site.
详细描述
LuSeed Vascular will sponsor the study and the study will assess early safety and feasibility of the LuSeed Aneurysm Embolization System for the treatment of unruptured intracranial aneurysms (IA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients indicated for treatment of unruptured intracranial aneurysms (IA) according to AHA / ASA Guidelines.
- •Age 18-80 years at screening
- •Patients who are suitable for non-emergency endovascular embolization of saccular IAs
- •The IA must have had the following characteristics:
- •IA located in bifurcation in the anterior or posterior circulation
- •IA dimensions appropriate for treatment with LuSeed- Vascular Embolization Device per implant size selection guidelines as outlined in the Instructions for
- •Use (IFU) and as follows:
- •IA Width: 2.5-5.5[mm]
- •IA Neck: 2.0-5.0[mm]
- •IA Height: min 4.0 [mm]- device short configuration, min 5.0 [mm]-device long configuration • The AI must meet the definition of a "wide-neck" aneurysm.
- •Patient is willing and able to participate in the study for the duration of the study follow-up and can comply with study requirements
- •Patient able to give their informed consent can be included in this study.
排除标准
- •Ruptured intracranial aneurysm
- •Patient anatomy or physiology considered unsuitable for endovascular treatment as determined by imaging Core Lab
- •Contraindication for arterial access
- •Intracranial aneurysm neck diameter less than 2mm or greater than 5 mm
- •Intracranial aneurysm sac diameter less than 2.5mm or greater than 5.5mm
- •Intracranial aneurysm minimum height less than 4.0 mm
- •Target Intracranial aneurysm contains other devices/implants (e.g., coils)
- •Stenosis of the target IA's parent vessel >50%
- •Known allergy to platinum, nickel, or titanium
- •Known allergy to contrast agents
- •Absolute contraindication to anticoagulation or antiplatelet therapy
- •Anticoagulation medications such as warfarin that cannot be discontinued
- •Pregnant, breastfeeding or planning pregnancy within next 12 months
- •Acute or chronic renal failure (stage III or IV by VARC-3 criteria)
- •Cerebral embolism, stroke, or TIA in past 6 months
- •Myocardial infarction in the past 6 months
- •Any other medical issue within the brain that would preclude device implantation (such as brain surgery, radiation in the target area of intervention from an external beam source, acute traumatic craniocerebral injury, etc.)
- •Patient had any circulatory, neurovascular, cardiovascular, or neurologic conditions that resulted in unstable neurological symptoms at screening.
- •Patient had physical, neurologic or psychiatric conditions which precluded his/her ability to comply with all aspects of the screening, evaluation, treatment, and the postprocedure follow-up schedule.
- •Other medical conditions that cause an inability to comply with study requirements and/or that could increase the risk of neurovascular procedures (e.g., extreme frailty, liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)
- •Patient had a life expectancy of less than 12 months.
- •Current participation in another study with investigational devices or drugs that would confound the effect of the study outcomes.
结局指标
主要结局
Primary Safety Endpoint
时间窗: 30 Days Post Study Procedure
Death of any non-accidental cause, Procedure or Device Related Death or Any Major Disabling Stroke \*An independent Medical Monitor (IMM) will adjudicate all data used for safety endpoint analyses
Primary Feasibility Endpoint
时间窗: Day 0
Technical Success as defined by: a. Success in accessing target intracranial aneurysm (IA) with the LuSeed Aneurysm Embolization System b. Successful visual confirmation of the LuSeed Aneurysm Embolization System Successful deployment and detachment of the LuSeed Aneurysm Embolization System
次要结局
- Secondary Effectiveness Endpoints(6-months and 12-months after treatment)
- Secondary Safety Endpoints(12 months)
- Secondary Effectiveness Endpoints(Day-30, 6-months and 12-months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)Advanced solid tumoursMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-509633-39-00Anaveon AG240
已完成
1 期
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years2023-506396-94-00Osivax48
已完成
1 期
Study to Assess the Minimum Effective Concentration of NVK031 on Pupillary Constriction andDistance Vision in Healthy Volunteersormal eye functionNormal eye functionEye - Normal eye development and functionACTRN12621000351819evakar, Inc.36
进行中（未招募）
1 期
First trial testing safety and efficacy of IMGN151 in women with recurrent endometrial and ovarian cancerRecurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersMedDRA version: 20.0Level: PTClassification code: 10016180Term: Fallopian tube cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10061328Term: Ovarian epithelial cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014736Term: Endometrial cancer recurrent Class: 100000004864CTIS2023-506842-22-00Immunogen Inc.259
招募中
1 期
Phase I Dose Finding Study in Patients with HER2-Positive Advanced Solid TumorsHER2-Positive Advanced Solid TumorsCancer - Any cancerACTRN12620000592943Conjugate Light (Australia) Pty Ltd13